Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Lipocine ( (LPCN) ) is now available.
On June 26, 2025, Lipocine Inc. announced the dosing of the first patient in its Phase 3 clinical trial for LPCN 1154, an investigational oral treatment for postpartum depression. This trial, conducted in an outpatient setting without medical monitoring, aims to support an NDA submission in mid-2026. The study involves a two-arm, randomized, blinded design comparing LPCN 1154 to a placebo, with primary and secondary endpoints focusing on depression and anxiety severity. The trial’s results could position LPCN 1154 as a rapid relief, standard-of-care treatment for postpartum depression, addressing a significant unmet need in the market.
The most recent analyst rating on (LPCN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
Lipocine’s financial recovery is promising, with a strong balance sheet and reduced operational volatility. However, challenges remain in achieving consistent profitability and cash flow generation. Technical indicators show mixed signals, and the high P/E ratio suggests overvaluation, creating a cautious outlook.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Lipocine Inc. is a biopharmaceutical company that utilizes its proprietary technology platform to develop innovative products with effective oral delivery. The company focuses on creating differentiated, patient-friendly oral delivery options targeting large addressable markets with significant unmet medical needs. Lipocine’s clinical development candidates include treatments for postpartum depression, refractory epilepsy, essential tremor, obesity management, and liver cirrhosis.
Average Trading Volume: 43,510
Technical Sentiment Signal: Sell
Current Market Cap: $17.28M
See more insights into LPCN stock on TipRanks’ Stock Analysis page.